Profile of prostanoid release following antigen challenge in vivo in the skin of man
Authors:
- 1 December 1991
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 125 (6) , 529-534
Abstract
We have previously characterized the kinetics of prostaglandin D2 (PGD2) production at cutaneous sites of allergic inflammation employing a blister-chamber model. In this study, a more complete profile of prostaglandins released in vivo was obtained. PGD2 release, as measured by radioimmunoassay and by combined gas chromatography-mass spectrometry, was evident within 1 h after antigen challenge with maximal levels occurring 3-4 h post-challenge. The 11-ketoreductase metabolite of PGD2, 9 alpha, 11 beta-prostaglandin F2 was present in blister fluid from three of six patients at the time of maximal levels of PGD2. The stable non-enzymatic hydrolysis product of prostacyclin, 6-keto-prostaglandin F1 alpha, was significantly elevated in blister fluid from five of six patients following antigen challenge. In these subjects, the levels of 6 kappa-PGF1 alpha were highest in samples obtained 1 and 2 h after antigen challenge and remained significantly elevated until 5 h post-challenge. Levels of prostaglandin E2, prostaglandin F2 alpha and thromboxane B2 did not vary significantly. These studies suggest that following antigen challenge two fatty-acid cyclo-oxygenase products of arachidonic acid are released, PGD2 and prostacyclin. The 11-ketoreductase metabolism of PGD2 to 9 alpha, 11 beta-PGF2 could represent a mechanism by which the biological effects of PGD2 are prolonged in cutaneous tissue. The presence of 6 kappa-PGF1 alpha in the blister fluid suggests that significant prostacyclin release occurs as the result of antigen challenge and could represent a mechanism by which the prolonged microvascular response in cutaneous tissue may occur.Keywords
This publication has 30 references indexed in Scilit:
- Interleukin-1 is released at sites of human cutaneous allergic reactionsJournal of Allergy and Clinical Immunology, 1990
- Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration.Journal of Clinical Investigation, 1989
- Prostaglandin D2 and histamine during the immediate and the late-phase components of allergic cutaneous responsesJournal of Allergy and Clinical Immunology, 1988
- 9 alpha,11 beta-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways.Journal of Clinical Investigation, 1987
- Observations on Nasal Late Phase ReactionsImmunological Investigations, 1987
- Prostaglandin D2 and histamine release in cold urticariaJournal of Allergy and Clinical Immunology, 1986
- Increased Production of Prostaglandin D2 in Patients with Systemic MastocytosisNew England Journal of Medicine, 1980
- Histamine stimulates prostacyclin synthesis in cultured human umbilical vein endothelial cellsBiochemical and Biophysical Research Communications, 1980
- An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergenJournal of Allergy and Clinical Immunology, 1980
- In vivo studies of mediator release in cold urticaria and cholinergic urticariaJournal of Allergy and Clinical Immunology, 1975